Stockreport

AbbVie slips after revising guidance to reflect earnings impact [Seeking Alpha]

Cerevel Therapeutics Holdings, Inc.  (CERE) 
PDF The North Chicago, Illinois-based pharma giant said its full-year and Q1 2024 guidance for adjusted diluted earnings will now stand at $10.97–$1.17 and $2.18–$2.22 per [Read more]